BCL2 and plasma cell myeloma: This ability of Bcl-2 inhibitors to overcome Btz resistance has not been described in the in vitro generated cell lines, however, none of them bear the t(11;14) translocation which sensitizes myeloma cells to Bcl-2 inhibitors.